Download PDF
Aktuelle Rheumatologie 2023; 48(01): 43-49
DOI: 10.1055/a-1927-0406
Übersichtsarbeit

Behçet- und Cogan-Syndrom

Die Vaskulitiden variabler GefäßeBehçet’s and Cogan’s SyndromesThe Variable Vessel Vasculitides
Ina Kötter
1   Department of Internal Medicine III, Division of Rheumatology and Inflammatory Rheumatic Diseases, University Hospital Hamburg Eppendorf, Germany
2   Rheumatology and Immunology, Klinikum Bad Bramstedt GmbH, Bad Bramstedt, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Das Behçet- und das Cogan-Syndrom bilden zusammen die Gruppe der Vaskulitiden der variablen Gefäße nach der Chapel-Hill Nomenklatur. Sie können Arterien und Venen jeder Größe betreffen. Wie die Bezeichnung „Syndrom“ bei beiden Krankheitsbildern bereits widerspiegelt, können beide individuell sehr unterschiedliche Symptome bieten. Beide zählen formal zu den seltenen Erkrankungen, wobei das Cogan-Syndrom mit der Beschreibung von lediglich einigen hundert Fällen weltweit deutlich seltener als das Behςet-Syndrom ist. Für letzteres gibt es Diagnose- und Klassifikationskriterien, und auch europäische (EULAR, European Alliance of Associations for Rheumatology) Therapieempfehlungen. Symptomatologie, Diagnostik und Therapie, aber auch einige Überlegungen zur Pathogenese dieser beiden Vaskulitiden werden im Folgenden beleuchtet.

Abstract

Behçet’s syndrome and Cogan’s syndrome constitute the group of variable vessel vasculitides in the Chapel-Hill Nomenclature. They involve arteries and veins of all sizes. As reflected in the name “syndrome”, both diseases can manifest with different individual symptoms. Both formally are rare diseases, but the Cogan syndrome is much rarer than Behçet`s. For the latter, there are diagnosis and classification criteria as well as European (EULAR, European Alliance of Associations for Rheumatology) treatment recommendations. The symptomatology, diagnostic measures and treatment as well as some considerations about pathogenesis will be discussed in this article.

Schlüsselwörter

Behçet - Cogan - Pathogenese - Diagnose - Therapie

Key words

Behçet - Cogan - pathogenesis - diagnosis - treatmentonline publiziert 2022


Publication History

Article published online:
02 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Behcet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wschr 1937; 105: 1152-1157
    PubMedGoogle Scholar
  • 2 Adamantiades B. A case of relapsing iritis with hypopion (in Greek). Archia Iatrikis Etairas (Proceedings of hte Medical Society of Athens). 1930 586-539
    PubMedGoogle Scholar
  • 3 Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013; 17: 603-606
    CrossrefPubMedGoogle Scholar
  • 4 Norton EW, Cogan DG. Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms; a long-term follow-up. AMA Arch Ophthalmol 1959; 61: 695-697
    CrossrefPubMedGoogle Scholar
  • 5 Cogan DG. Nonsyphilitic interstitial keratitis with vestibuloauditory symptoms; report of four additional cases. Arch Ophthal 1949; 42: 42-49
    CrossrefPubMedGoogle Scholar
  • 6 Mahr A, Maldini C. [Epidemiology of Behcet’s disease]. Rev Med Interne 2014; 35: 81-89
    PubMedGoogle Scholar
  • 7 Altenburg A, Mahr A, Maldini C. et al. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany : Current data]. Ophthalmologe 2012; 109: 531-541
    PubMedGoogle Scholar
  • 8 Durtette C, Hachulla E, Resche-Rigon M. et al. Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev 2017; 16: 1219-1223
    CrossrefPubMedGoogle Scholar
  • 9 Gluth MB, Baratz KH, Matteson EL. et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006; 81: 483-488
    CrossrefPubMedGoogle Scholar
  • 10 McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297
    CrossrefPubMedGoogle Scholar
  • 11 Deng Y, Zhu W, Zhou X. Immune Regulatory Genes Are Major Genetic Factors to Behcet Disease: Systematic Review. The open rheumatology journal 2018; 12: 70-85
    CrossrefPubMedGoogle Scholar
  • 12 Tong B, Liu X, Xiao J. et al. Immunopathogenesis of Behcet’s Disease. Frontiers in immunology 2019; 10: 665
    CrossrefPubMedGoogle Scholar
  • 13 McGonagle D, Aydin SZ, Gul A. et al. Reply to: Behcet’s disease: an MHC-I-opathy?. Clin Exp Rheumatol 2017; 35: 6
    PubMedGoogle Scholar
  • 14 Gul A, Ohno S. HLA-B*51 and Behcet Disease. Ocul Immunol Inflamm 2012; 20: 37-43
    CrossrefPubMedGoogle Scholar
  • 15 Bhandari GS, Duggal L, Jain N. et al. Cogan syndrome: An autoimmune eye and ear disease with systemic manifestations. Natl Med J India 2019; 32: 349-351
    CrossrefPubMedGoogle Scholar
  • 16 Kamakura T, Lee DJ, Herrmann BS. et al. Histopathology of the Human Inner Ear in the Cogan Syndrome with Cochlear Implantation. Audiol Neurootol 2017; 22: 116-123
    CrossrefPubMedGoogle Scholar
  • 17 Kessel A, Vadasz Z, Toubi E. Cogan syndrome – pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2014; 13: 351-354
    CrossrefPubMedGoogle Scholar
  • 18 Kotter I. Behcet’s syndrome: Current diagnostics and treatment. Z Rheumatol 2020; 79: 873-882
    PubMedGoogle Scholar
  • 19 Kotter I, Lotscher F. Behcet’s Syndrome Apart From the Triple Symptom Complex: Vascular, Neurologic, Gastrointestinal, and Musculoskeletal Manifestations. A Mini Review. Front Med (Lausanne) 2021; 8: 639758
    CrossrefPubMedGoogle Scholar
  • 20 Yazici H, Seyahi E, Hatemi G. et al. Behcet syndrome: a contemporary view. Nat Rev Rheumatol 2018; 14: 107-119
    CrossrefPubMedGoogle Scholar
  • 21 Seyahi E. Phenotypes in Behcet’s syndrome. Intern Emerg Med 2019; 14: 677-689
    CrossrefPubMedGoogle Scholar
  • 22 Zou J, Luo JF, Shen Y. et al. Cluster analysis of phenotypes of patients with Behcet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther 2021; 23: 45
    CrossrefPubMedGoogle Scholar
  • 23 [Anonym] Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078-1080
    PubMedGoogle Scholar
  • 24 International Team for the Revision of the International Criteria for Behcet’s D. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338-347
    CrossrefPubMedGoogle Scholar
  • 25 Antonios N, Silliman S. Cogan syndrome: an analysis of reported neurological manifestations. Neurologist 2012; 18: 55-63
    CrossrefPubMedGoogle Scholar
  • 26 Casselman JW, Majoor MH, Albers FW. MR of the inner ear in patients with Cogan syndrome. AJNR Am J Neuroradiol 1994; 15: 131-138
    PubMedGoogle Scholar
  • 27 Hatemi G, Christensen R, Bang D. et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 2018; 808-818
    PubMedGoogle Scholar
  • 28 Kural-Seyahi E, Fresko I, Seyahi N. et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76
    CrossrefPubMedGoogle Scholar
  • 29 Hatemi G, Mahr A, Ishigatsubo Y. et al. Trial of Apremilast for Oral Ulcers in Behcet’s Syndrome. N Engl J Med 2019; 381: 1918-1928
    CrossrefPubMedGoogle Scholar
  • 30 Merrill PT, Vitale A, Zierhut M. et al. Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials. Ocul Immunol Inflamm 2020; DOI: 10.1080/09273948.2020.1757123:. 1-7
    CrossrefPubMedGoogle Scholar
  • 31 Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm 2018; 26: 1005-1014
    CrossrefPubMedGoogle Scholar
  • 32 Padoan R, Cazzador D, Pendolino AL. et al. Cogan’s syndrome: new therapeutic approaches in the biological era. Expert Opin Biol Ther 2019; 19: 781-788
    CrossrefPubMedGoogle Scholar
  • 33 Kougkas N, Bertsias G, Stratoudaki R. et al. Successful treatment of Cogan’s syndrome with tocilizumab. Scand J Rheumatol 2021; 50: 330-331
    CrossrefPubMedGoogle Scholar
  • 34 Venhoff N, Thiel J, Schramm MA. et al. Case Report: Effective and Safe Treatment With Certolizumab Pegol in Pregnant Patients With Cogan’s Syndrome: A Report of Three Pregnancies in Two Patients. Front Immunol 2020; 11: 616992
    CrossrefPubMedGoogle Scholar
  • 35 Bovo R, Ciorba A, Trevisi P. et al. Cochlear implant in Cogan syndrome. Acta Otolaryngol 2011; 131: 494-497
    CrossrefPubMedGoogle Scholar
  • 36 D’Aguanno V, Ralli M, de Vincentiis M. et al. Optimal management of Cogan’s syndrome: a multidisciplinary approach. J Multidiscip Healthc 2018; 11: 1-11
    CrossrefPubMedGoogle Scholar